pomalidomide has been researched along with Renal Insufficiency in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Assadourian, S; Campana, F; Dimopoulos, MA; Harrison, SJ; Leleu, X; Liberati, AM; Malinge, L; Miles Prince, H; Moreau, P; Ocio, EM; Richardson, PG; Sémiond, D; van de Velde, H; Yong, K | 1 |
| Tomlinson, R | 1 |
| Li, Y; Liu, L; Palmisano, M; Wang, X; Xu, Y; Zhou, S | 1 |
| Alegre, A; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Hong, K; Ivanova, V; Jacques, C; Karlin, L; Knop, S; Lacy, MQ; Martinez-Lopez, J; Moreau, P; Oriol, A; San Miguel, J; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, MH | 1 |
| Baz, R; Cavo, M; Delforge, M; Dimopoulos, MA; Goldschmidt, H; Hong, K; Jagannath, S; Moreau, P; Palumbo, A; Richardson, P; San Miguel, JF; Siegel, DS; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, M | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Terpos, E | 1 |
| Benjamin, R; Cerner, A; Cheesman, S; D'sa, S; Jenner, M; Maciocia, N; Maciocia, P; Melville, A; Popat, R; Rabin, N; Ramasamy, K; Rismani, A; Schey, S; Sharpley, F; Streetly, M; Yong, K | 1 |
1 review(s) available for pomalidomide and Renal Insufficiency
| Article | Year |
|---|---|
Current treatments for renal failure due to multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Renal Insufficiency; Thalidomide | 2016 |
2 trial(s) available for pomalidomide and Renal Insufficiency
| Article | Year |
|---|---|
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Renal Insufficiency; Salvage Therapy; Survival Rate; Thalidomide | 2021 |
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
4 other study(ies) available for pomalidomide and Renal Insufficiency
| Article | Year |
|---|---|
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Pain; Prognosis; Renal Insufficiency; Serum Albumin; Thalidomide | 2018 |
Population pharmacokinetics of pomalidomide.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Immunologic Factors; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Multiple Myeloma; Renal Insufficiency; Sex Factors; Thalidomide | 2015 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Renal Insufficiency; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Kidney Function Tests; Male; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |